ROMULUS Navy Evaluation And New Production Line Might Change The Case For Investing In HII

هنتنغتون إينغلس للصناعات

Huntington Ingalls Industries, Inc.

HII

0.00

  • In early June 2026, Huntington Ingalls Industries reported that its ROMULUS unmanned surface vessel advanced into the U.S. Navy’s Medium Unmanned Surface Vessel evaluation phase, while partner Bayou Metal Supply & Manufacturing opened a dedicated production line in Louisiana to accelerate fabrication of ROMULUS hull structures.
  • This combination of program progress and expanded industrial capacity highlights Huntington Ingalls Industries’ push to scale its Odyssey-enabled autonomous maritime systems alongside traditional shipbuilding for future naval missions.
  • Next, we’ll explore how ROMULUS’s move into Navy evaluation, supported by a new dedicated production line, influences Huntington Ingalls Industries’ investment narrative.

Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.

Huntington Ingalls Industries Investment Narrative Recap

To own Huntington Ingalls Industries, you need to believe that its core shipbuilding backlog and growing autonomous systems portfolio can work together to support long-term defense demand. The ROMULUS evaluation milestone and new hull production line speak directly to the short term catalyst around unmanned systems, while also slightly easing the risk that a future pivot away from large manned ships could leave HII’s fixed shipyard base underutilized.

The ROMULUS news sits alongside HII’s April 21 plan to expand ROMULUS 151 production at Breaux Brothers and apply its HYPR digital manufacturing initiative. Together, these updates point to a broader push to industrialize autonomous vessels, which could matter if Mission Technologies and unmanned platforms become a more meaningful counterweight to any volatility tied to long cycle Navy contracts.

But while ROMULUS may help, investors still need to be aware that heavy reliance on large, long cycle U.S. Navy programs leaves Huntington Ingalls exposed if...

Huntington Ingalls Industries' narrative projects $14.6 billion revenue and $912.4 million earnings by 2029. This requires 5.4% yearly revenue growth and about a $307 million earnings increase from $605.0 million today.

Uncover how Huntington Ingalls Industries' forecasts yield a $407.09 fair value, a 39% upside to its current price.

Exploring Other Perspectives

HII 1-Year Stock Price Chart
HII 1-Year Stock Price Chart

While consensus focuses on steady growth, the most optimistic analysts were already modeling revenues of about US$15.6 billion and earnings of roughly US$1.1 billion by 2029, assuming Mission Technologies outperforms; the ROMULUS update could either support that upbeat view or highlight how much still hinges on whether autonomous platforms really offset the risk that demand for traditional large ships weakens over time.

Explore 5 other fair value estimates on Huntington Ingalls Industries - why the stock might be worth as much as 49% more than the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

  • A great starting point for your Huntington Ingalls Industries research is our analysis highlighting 5 key rewards and 2 important warning signs that could impact your investment decision.
  • Our free Huntington Ingalls Industries research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Huntington Ingalls Industries' overall financial health at a glance.

No Opportunity In Huntington Ingalls Industries?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

  • The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
  • AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
  • We've uncovered the 10 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.